People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Intensity Therapeutics, Inc. | — | Biotechnology | Seed | $4.3M | $14.2M | 2024 |
Mark A. Goldberg at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark A. Goldberg on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Thomas I. H. Dubin | 1 | 2 |
| Lewis H. Bender | 1 | 2 |
| Ian B. Walters, M.D. | 1 | 1 |
| Daniel H. Donovan | 1 | 1 |
| Joseph I.H. Talamo | 1 | 1 |
| Emer H. Leahy | 1 | 1 |
| Robert B. Cooke | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.